Expand Medicare beneficiaries' access to more affordable prescription drugs.

Doris O. Matsui · California · Democratic

policy impact 3.00 specificity 4.00 extraction confidence 99%

Contest this claim

Occurrences

introduced the Ensuring Access to Lower-Cost Medicines for Seniors Act, bipartisan legislation to expand Medicare beneficiaries’ access to more affordable prescription drugs

Introduces legislation aimed at lowering seniors' prescription drug costs.

Press Releases | Congresswoman Doris Matsui
primary · press_release · model gpt-5.4-mini

Evidence

Ms. Matsui (for herself, Mrs. Miller-Meeks, and Mr. Auchincloss) introduced the following bill; which was referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means... This Act may be cited as the “Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026.”

Matsui introduced a bill to require Medicare Part D formularies to include certain lower-cost generic drugs and biosimilars, with referral to Energy and Commerce and Ways and Means. This is a concrete legislative effort toward the claim, but it is only introduction and referral, not enactment or implementation.

unresolved same_term A for effort

H.R. 8143 (IH) - Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026. - BILLS-119hr8143ih | Content Details | GovInfo
secondary · model gpt-5.4-mini · confidence 95%

Contest this evidence item

On May 18, 2026, the Supreme Court declined to hear pharmaceutical company appeals, leaving the Medicare drug price negotiation program intact and allowing lower Medicare drug prices to continue.

A recent Supreme Court action preserved the Inflation Reduction Act's Medicare drug negotiation program, confirming that the federal mechanism to lower prescription drug costs for beneficiaries remains in force.

delivered same_term

Supreme Court rejects appeals from drug manufacturers over Medicare price negotiations
secondary · model gpt-5.4-mini · confidence 94%

Contest this evidence item

Assessments

partial same_term

The record shows Matsui made a concrete same-term effort by introducing the Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026, which would have expanded access to lower-cost drugs for Medicare beneficiaries, but that bill was only introduced and referred, not enacted. Separately, Medicare beneficiaries did retain and continue to benefit from lower drug prices through the existing Medicare negotiation program, but the provided evidence does not show Matsui personally delivered or materially drove that outcome. Under a federal candidate-credit standard, that supports limited credit for advancement toward the promise, not full delivery.

provider codex_cli · model gpt-5.4 · confidence 84%

delivered same_term

The promised outcome was broadly achieved at the federal level through enacted Medicare prescription drug reforms in the Inflation Reduction Act of 2022, including Medicare drug price negotiation authority, insulin cost caps, vaccine cost-sharing elimination, inflation rebates, and a Part D out-of-pocket cap. Matsui was a sitting House Democrat when the Act passed the House on August 12, 2022 and was signed into law on August 16, 2022, so her vote materially advanced an enacted federal outcome in office. Her 2026 bill to require Part D formularies to include certain lower-cost generics and biosimilars is additional same-term effort, but delivery does not depend on that pending bill.

provider codex_cli · model gpt-5.5 · confidence 82%